RxDoctor Payments Data

Peter Beitsch, MD

Surgical Oncology · Dallas, TXNPI 1336187731

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $57,255 of the $61,927 with a category attached, or 92.5%. Icad, Inc accounts for 75.6% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2020 at $26,590 and has fallen 97.8% since, to $587 in 2025. Among surgical oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$61,927in general payments, 2019–2025

Across 102 payments — averaging $607.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Icad, Inc$47K
  • Impedimed, Inc.$6K
  • Merck$3K
  • AstraZeneca$2K
  • Endomagnetics Ltd$651
  • Bard Peripheral Vascular, Inc.$600
  • plus $3K from 27 others

What the payments were for

  • Consulting fees$57,25592%
  • Speaking & faculty fees$9001%
  • Food & beverage$3,6606%
  • Education$1120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,927 in reported general payments places this provider in the 95th percentile of 191 surgical oncology providers in Texas.

See all surgical oncology providers in Texas

Medicare billing

Part B allowed, 2024
$305,692
Medicare patients
338
Services billed
1,841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Letrozole74$1,837
Anastrozole44$605
Tamoxifen Citrate19$560
Tramadol Hcl86$280
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim33$175
Acetaminophen-CodeineAcetaminophen With Codeine21$121

Paid to pharmacies, not to this prescriber.

Other surgical oncology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →